SCHEDULE: Vanguard Group Amends Stake in Iovance Biotherapeutics
Beneficial Ownership Disclosure
The Vanguard Group has filed an amended Schedule 13G, disclosing a 7.50% beneficial ownership stake in Iovance Biotherapeutics Inc., totaling 25,076,472 common shares.
Summary
- The Vanguard Group, an investment adviser based in Pennsylvania, has filed Amendment No. 5 to its Schedule 13G regarding Iovance Biotherapeutics Inc.
- As of the event date of June 30, 2025, Vanguard beneficially owns an aggregate of 25,076,472 shares of Iovance Biotherapeutics Inc. Common Stock.
- This aggregate amount represents 7.50% of the class of securities.
- Vanguard holds sole voting power over 0 shares, shared voting power over 158,020 shares, sole dispositive power over 24,600,993 shares, and shared dispositive power over 475,479 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a neutral, routine regulatory disclosure of beneficial ownership by a large institutional investor, indicating continued holding rather than a significant change in investment thesis.
Positives
- A significant beneficial ownership stake by a major institutional investor like The Vanguard Group can signal long-term confidence in the company's prospects.
Risks
- The filing itself does not introduce new risks but reflects the inherent market risks associated with holding common stock in a biotechnology company.
Future Outlook
No forward-looking statements or guidance are provided in this beneficial ownership disclosure.
Industry Context
This filing is a routine disclosure by a large asset manager, common in the biotechnology sector where institutional investment is significant for capital-intensive research and development.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially influencing market perception.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement |
| 07/29/2025 | Signature date of the filing |
Keywords
Iovance Biotherapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.